Insmed to Present at Leerink Swann Rare Disease Roundtable
25 Septembre 2013 - 2:30PM
Marketwired
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company
focused on developing and commercializing an inhaled anti-infective
to treat patients battling serious lung diseases in orphan
indications that are often life-threatening, announces Will Lewis,
Insmed's President and Chief Executive Officer, will deliver a
corporate overview at the upcoming Leerink Swann Rare Disease
Roundtable taking place October 2, 2013 at the Parker Meridian, New
York. Mr. Lewis will be presenting at 1:00 p.m. Eastern time.
Mr. Lewis' presentation will be webcast live on the internet and
can be accessed by visiting the investors section of the company's
website at www.insmed.com. A replay of the webcast will be archived
on the Insmed website for 90 days following the presentation.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious lung diseases.
Insmed is focused on the development and commercialization of
ARIKACE®, or liposomal amikacin for inhalation, for at least two
identified orphan patient populations: cystic fibrosis (CF)
patients with Pseudomonas aeruginosa lung infections and patients
with non-tuberculous mycobacteria (NTM) lung infections. For more
information, please visit http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements that are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Words, and variations of words, such as "intend,"
"expect," "will," "anticipate," "believe," "continue," "propose"
and similar expressions are intended to identify forward-looking
statements. Investors are cautioned that such statements in this
release, including statements relating to the status, results and
timing of results of preclinical studies and clinical trials and
preclinical and clinical data and the anticipated benefits of
Insmed's products, constitute forward-looking statements that
involve risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements.
Such risks and uncertainties include, without limitation, failure
or delay of U.S. Food and Drug Administration and other regulatory
reviews and approvals, competitive developments affecting our
product candidates, delays in product development or clinical
trials or other studies, patent disputes and other intellectual
property developments relating to our product candidates,
unexpected regulatory actions, delays or requests, the failure of
clinical trials or other studies or results of clinical trials or
other studies that do not meet expectations, inability to
successfully develop our product candidates or receive necessary
regulatory approvals, inability to make product candidates
commercially successful, changes in anticipated expenses, and other
risks and challenges detailed in our filings with the U.S.
Securities and Exchange Commission, including our Annual Report on
Form 10-K for the year ended December 31, 2012. Investors are
cautioned not to place undue reliance on any forward-looking
statements that speak only as of the date of this news release. We
undertake no obligation to update these forward-looking statements
to reflect events or circumstances or changes in our
expectations.
Investor Relations Contact: LHA Anne Marie Fields Senior
Vice President 212-838-3777 afields@lhai.com Bruce Voss Managing
Director 310-691-7100 bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024